Sutro Biopharma (STRO) Net Income (2017 - 2026)
Sutro Biopharma (STRO) posted Net Income of -$46.8 million for Q4 2025, up 17.77% sequentially from -$56.9 million in Q3 2025, and up 35.46% YoY from -$34.5 million in Q4 2024.
Sutro Biopharma (STRO) Net Income (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported Net Income for 9 years, with the latest figure at -$46.8 million in Q4 2025.
- Quarterly Net Income rose 35.46% year-over-year to -$46.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$182.7 million (up 19.66% YoY) and the FY2025 annual result came in at -$191.1 million, up 15.99% from the prior year.
- Net Income climbed to -$46.8 million in Q4 2025 per STRO's latest filing, from -$56.9 million in the prior quarter.
- Over five years, Net Income peaked at $31.1 million in Q4 2023 and troughed at -$72.4 million in Q4 2024.
- A 5-year average of -$36.6 million and a median of -$38.8 million in 2022 frame the typical range for Net Income.
- The sharpest annual moves came in 2023 and 2024: Net Income jumped 189.78% in 2023, then tumbled 333.26% in 2024.
- Over 5 years, Net Income stood at -$38.1 million in 2021, then climbed by 9.26% to -$34.6 million in 2022, then surged by 189.78% to $31.1 million in 2023, then plunged by 333.26% to -$72.4 million in 2024, then surged by 35.46% to -$46.8 million in 2025.
- According to Business Quant data, Net Income over the past three periods registered -$46.8 million, -$56.9 million, and -$11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | -38.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.53 Mn |
| Dec 31, 2025 | -46.76 Mn |
| Sep 30, 2025 | -56.86 Mn |
| Jun 30, 2025 | -11.50 Mn |
| Mar 31, 2025 | -67.63 Mn |
| Dec 31, 2024 | -72.44 Mn |
| Sep 30, 2024 | -48.79 Mn |
| Jun 30, 2024 | -48.02 Mn |
| Mar 31, 2024 | -58.21 Mn |
| Dec 31, 2023 | 31.06 Mn |
| Sep 30, 2023 | -49.28 Mn |
| Jun 30, 2023 | -38.52 Mn |
| Mar 31, 2023 | -50.05 Mn |
| Dec 31, 2022 | -34.59 Mn |
| Sep 30, 2022 | -19.49 Mn |
| Jun 30, 2022 | -26.01 Mn |
| Mar 31, 2022 | -39.11 Mn |
| Dec 31, 2021 | -38.13 Mn |
| Sep 30, 2021 | -30.90 Mn |
| Jun 30, 2021 | -6.15 Mn |